Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas

30 Nov 2018

Abstract excerpt

There is a pressing need for more effective therapies to treat patients with T-cell lymphomas (TCLs), including first-line approaches that increase the response rate to cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP) chemotherapy. We characterized the mitochondrial apoptosis pathway in cell lines and patient-derived xenograft (PDX) models of TCL and assessed the in vitro efficacy of BH3 mimetics,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immune Cell Function and Interaction
Share to Lymphoma Diagnosis and Treatment
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30498064
DOI: 10.1182/blood-2018-07-865527

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomasPMID 30498064Read ↗

BH3 Mimetics in Hematologic MalignanciesSemantic proximity Read ↗

Toward Targeting Antiapoptotic MCL-1 for Cancer TherapySemantic proximity Read ↗

The BCL2 family: from apoptosis mechanisms to new advances in targeted therapySemantic proximity Read ↗

Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugsSemantic proximity Read ↗

BH3 Mimetics for the Treatment of B-Cell Malignancies—Insights and Lessons from the ClinicSemantic proximity Read ↗

The mitochondrial anti-apoptotic dependencies of hematologic malignancies: from disease biology to advances in precision medicineSemantic proximity Read ↗

Mitochondrial apoptosis and BH3 mimeticsSemantic proximity Read ↗

BCL-2 Proteins in Pathogenesis and Therapy of B-Cell Non-Hodgkin LymphomasSemantic proximity Read ↗

BCL2-Family Dysregulation in B-Cell Malignancies: From Gene Expression Regulation to a Targeted Therapy BiomarkerSemantic proximity Read ↗

The BCL-2 arbiters of apoptosis and their growing role as cancer targetsSemantic proximity Read ↗

Targeting Mitochondrial Apoptosis to Overcome Treatment Resistance in CancerSemantic proximity Read ↗

Targeting anti‐apoptotic BCL 2 family proteins in haematological malignancies – from pathogenesis to treatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.